- Home
- NSIT vs SUPN Comparison
NSIT vs SUPN Comparison
Compare NSIT & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSIT
- SUPN
- Stock Information
- Founded
- NSIT 1988
- SUPN 2005
- Country
- NSIT United States
- SUPN United States
- Employees
- NSIT 14324
- SUPN N/A
- Industry
- NSIT EDP Services
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- NSIT Technology
- SUPN Health Care
- Exchange
- NSIT Nasdaq
- SUPN Nasdaq
- Market Cap
- NSIT 2.8B
- SUPN 2.6B
- IPO Year
- NSIT 1995
- SUPN 2012
- Fundamental
- Price
- NSIT $90.13
- SUPN $45.87
- Analyst Decision
- NSIT Buy
- SUPN Strong Buy
- Analyst Count
- NSIT 3
- SUPN 4
- Target Price
- NSIT $168.33
- SUPN $63.25
- AVG Volume (30 Days)
- NSIT 463.7K
- SUPN 1.0M
- Earning Date
- NSIT 10-30-2025
- SUPN 11-04-2025
- Dividend Yield
- NSIT N/A
- SUPN N/A
- EPS Growth
- NSIT N/A
- SUPN N/A
- EPS
- NSIT 4.21
- SUPN N/A
- Revenue
- NSIT $8,271,548,000.00
- SUPN $681,539,000.00
- Revenue This Year
- NSIT N/A
- SUPN $8.29
- Revenue Next Year
- NSIT $3.42
- SUPN $22.72
- P/E Ratio
- NSIT $21.42
- SUPN N/A
- Revenue Growth
- NSIT N/A
- SUPN 4.54
- 52 Week Low
- NSIT $89.50
- SUPN $29.16
- 52 Week High
- NSIT $181.92
- SUPN $57.65
- Technical
- Relative Strength Index (RSI)
- NSIT 15.32
- SUPN 38.10
- Support Level
- NSIT $89.50
- SUPN $43.11
- Resistance Level
- NSIT $111.54
- SUPN $57.34
- Average True Range (ATR)
- NSIT 3.26
- SUPN 2.55
- MACD
- NSIT -0.93
- SUPN -1.22
- Stochastic Oscillator
- NSIT 4.34
- SUPN 19.46
About NSIT Insight Enterprises Inc.
Insight Enterprises Inc is a Fortune IT provider engaged in helping businesses of all sizes, large enterprises, governments, schools, and healthcare organizations. The company has three geographic operating segments: North America, EMEA, and APAC. It generates maximum revenue from the North America segment. The company provides digital innovation, cloud/data center transformation, connected workforce, and supply chain optimization solutions and services.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.